CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis.

Breast Cancer Res Treat · 2023 · PMC10504109 · PMID 37584881

Europe PMC DOI

hedged sentences

0.0620

closest p · 1.2× alpha

0.1680

boldest claim

The sentences

did not quite reach statistical significancep = 0.062so close (0.05 < p ≤ 0.1)

Patients receiving CDK4/6i also had a longer OS in multivariate analysis but this did not quite reach statistical significance (HR 0.41, 95%CI 0.16–1.03, p = 0.062), although PS ≥ 2 was significantly predictive of shorter OS (HR 2.39, 95%CI 1.13–5.03, p = 0.021).

also in 132 other papers

did not reach statistical significancep = 0.168not close (p > 0.1)

Disease control rate at 4 months was numerically higher in the CDK4/6i compared to paclitaxel cohort, but did not reach statistical significance (77.8% vs. 59.4%, p = 0.168).

also in 45,344 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.